Journal article · 2002 · Open access
The NCEP ATP III Guidelines: Friend or Foe?
Preventive Cardiology, 5(3), 152–155 · Published 1 July 2002 · DOI 10.1111/j.1520-037x.2002.01689.x
In brief
“The NCEP ATP III Guidelines: Friend or Foe?” is a 2002 journal article by Patrick E. McBride, published in Preventive Cardiology. OpenAlex counts 3 citations as of 15 November 2026. It is open access: the full text is free to read at Preventive Cardiology.
- Citations
- 3
- Most cited in
- 2012 (1)
- References
- 9
- Authors
- 1
Abstract
Editor's Note: In the Perspectives section of the Spring 2002 issue of Preventive Cardiology, two clinicians presented their views and questions about the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). In this issue, the view from the ATP III is presented by Patrick E. McBride, MD, MPH. Dr. McBride is a member of the Expert Panel committee that drafted ATP III. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines provide an updated, evidence-based approach for screening and managing cholesterol in clinical practice.1 Updated guidelines are necessary due to newly published cholesterol research, and to enhance the identification of appropriate candidates for therapy according to the new scientific evidence. There are important additions to the new guidelines, such as risk stratification tools, new triglyceride and high-density lipoprotein cholesterol (HDL-C) classifications, and the use of a very practical measure called “non-HDL-cholesterol.” The components are presented in an Executive Summary1 and in many different forms, including a full report of the evidence and rationale for the guidelines, at the National Heart, Lung, and Blood Institute website (www.nhlbi.nih.gov/guidelines/cholesterol). One of the most important additions to the new ATP III guidelines is the incorporation of global risk assessment to identify high-and low-risk primary prevention patients and to guide treatment decisions. In order to stratify risk for setting lowdensity lipoprotein cholesterol (LDL-C) goals, the panel turned to the Framingham Heart Study, which has developed risk assessment tools that accurately estimate coronary heart disease (CHD) risk for US patients and with many other cultural groups. The ATP III risk assessment tool is based on new, 40-year follow-up data from Framingham, and provides the best evidence-based, risk stratification assessment currently available. The outcome of the research conducted by the Framingham Heart Study investigators, with input from the ATP III Expert Panel, is a practical patient assessment tool and treatment algorithm to optimize cholesterol treatment strategies. There are those who are critical of the new guidelines for adding the risk assessment, in addition to redefining the risk levels and treatment goals for serum lipoproteins.2, 3 This paper presents the basis of the new recommendations from ATP III, describes the practical use of these new features in busy practices, and addresses the concerns of these “ATP III skeptics.” Recent papers in this journal question the practicality of the new guidelines and the use of the new ATP III risk assessment.2, 3 These authors'…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
McBride, P. E. (2002). The NCEP ATP III Guidelines: Friend or Foe? Preventive Cardiology, 5(3), 152–155. https://doi.org/10.1111/j.1520-037x.2002.01689.x
MLA 9
McBride, Patrick E. “The NCEP ATP III Guidelines: Friend or Foe?” Preventive Cardiology, vol. 5, no. 3, 2002, pp. 152–155. https://doi.org/10.1111/j.1520-037x.2002.01689.x.
Chicago
McBride, Patrick E. 2002. “The NCEP ATP III Guidelines: Friend or Foe?” Preventive Cardiology 5 (3): 152–155. https://doi.org/10.1111/j.1520-037x.2002.01689.x.
Harvard
McBride, P. E. (2002) ‘The NCEP ATP III Guidelines: Friend or Foe?’, Preventive Cardiology, 5(3), pp. 152–155. doi:10.1111/j.1520-037x.2002.01689.x.
IEEE
P. E. McBride, “The NCEP ATP III Guidelines: Friend or Foe?,” Preventive Cardiology, vol. 5, no. 3, pp. 152–155, 2002, doi: 10.1111/j.1520-037x.2002.01689.x.
BibTeX
@article{mcbride2002ncep,
title = {{The NCEP ATP III Guidelines: Friend or Foe?}},
author = {McBride, Patrick E.},
journal = {Preventive Cardiology},
year = {2002},
volume = {5},
number = {3},
pages = {152--155},
doi = {10.1111/j.1520-037x.2002.01689.x},
url = {https://doi.org/10.1111/j.1520-037x.2002.01689.x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- NCEP ATP III guidelines
- cholesterol screening
- risk stratification
- Framingham risk score
- non-HDL cholesterol
- triglycerides
- HDL cholesterol
- coronary heart disease risk
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
McBride, P. E. (2002). The NCEP ATP III Guidelines: Friend or Foe? Preventive Cardiology, 5(3), 152–155. https://doi.org/10.1111/j.1520-037x.2002.01689.x
How many times has this paper been cited?
3 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Preventive Cardiology.
Who wrote this paper?
Patrick E. McBride.
What is the DOI of this paper?
10.1111/j.1520-037x.2002.01689.x. The permanent link is https://doi.org/10.1111/j.1520-037x.2002.01689.x.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.